ClinicalTrials.gg
CompletedNCT03433430Updated Sep 18, 2023Results posted

Multi-Center Pilot Study of truSculpt Device

An interventional study of truSculpt in Bulging and Body Fat, sponsored by Cutera Inc.. Completed at 3 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-18.

Sponsored by Cutera Inc. · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Aug 2017, registered Feb 2018).
Phase
Not applicable
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

An exploratory pilot study to evaluate the safety, efficacy and ergonomics of Cutera truSculpt device

Read the detailed description

This is a multi-center, pilot study in approximately 40 subjects, ages 18 to 65. Subjects will receive treatments and will be followed at 12 weeks post final treatment.

02

Conditions studied

  • Bulging
  • Body Fat
03

In context

Lead sponsor

Cutera Inc. is the lead sponsor of 42 studies on the registry; none are open to participants now.

Of its 19 completed or terminated interventional studies of FDA-regulated products, 19 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject must be able to read, understand and sign the Form.
  2. Female or Male, 18 to 65 years of age (inclusive).
  3. Subject has visible fat bulges in the area to be treated.
  4. Non-smoking for at least 6 months and willing to refrain from smoking for the duration of the study.
  5. Subject must agree to not undergo any other procedure(s) in the treatment region during the study period.
  6. Subject must adhere to the follow-up schedule and study instructions.
  7. Subject must adhere to the same diet and/or exercise routine throughout the study, and agree to maintain the same weight throughout the study.
  8. Willing to have digital photographs taken of the treatment area and agree to use of photographs for presentation, (educational and/or marketing), publications, and any additional marketing purposes.
  9. For female subjects: not pregnant or lactating and is either , surgically sterilized, or using a medically acceptable form of at least 3 months prior to enrollment and during the entire course of the study.

Exclusion criteria

Exclusion Criteria:

  1. Participation in a clinical trial of another device or drug within 3 months of study participation, or during the study period.
  2. Any type of prior cosmetic treatment to the target area within 6 months of study participation.
  3. Any prior invasive cosmetic surgery to the target area, such as liposuction.
  4. Has a pacemaker, internal defibrillator, implantable cardioverter-defibrillator, nerve stimulator implant, cochlear implant or any other electronically, magnetically or mechanically activated implant.
  5. Has metal implant(s) within the body, such as artificial heart valves.
  6. Significant uncontrolled concurrent illness that in the opinion of the Investigator would make the subject unsuitable for inclusion.
  7. History of any disease or condition that could impair wound healing.
  8. History of keloid formation, hypertrophic scarring or abnormal/delayed wound healing.
  9. Skin abnormality in the treatment area that in the opinion of the Investigator would make the subject unsuitable for inclusion.
  10. Currently undergoing systemic chemotherapy or radiation treatment for cancer, or history of treatment in the target area within 3 months of study participation.
  11. As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study or a condition that would compromise the subject's ability to comply with the study requirements.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Other
    truSculpt

    truSculpt treatment

    Device: truSculpt

Interventions

  • DevicetruSculpt

    Subjects will receive utreatments and will be followed at 12 weeks post final treatment.

06

What researchers measure

Primary outcomes

  1. Body Fat Assessment by Investigator

    Degree of Improvement in body fat as assessed by Investigator using the Global Aesthetic Improvement Scale (GAIS:) +4=Very Significant Improvement, +3=Significant Improvement, +2=Moderate Improvement, +1=Mild Improvement, and 0=No Change Higher scores indicate better outcomes

    Time frame: 12 weeks post final treatment

07

Results

Posted Sep 18, 2023

Participant flow

Participant flow — Overall Study
MilestonetruSculpt
Started9
Completed8
Not completed1

Outcome measures

PrimaryBody Fat Assessment by Investigator

Degree of Improvement in body fat as assessed by Investigator using the Global Aesthetic Improvement Scale (GAIS:) +4=Very Significant Improvement, +3=Significant Improvement, +2=Moderate Improvement, +1=Mild Improvement, and 0=No Change Higher scores indicate better outcomes

Time frame:
12 weeks post final treatment
Reported as:
Mean · score on a scale
Body Fat Assessment by Investigator
score on a scaletruSculpt
Body Fat Assessment by Investigator1.88 ± 1.13

Adverse events

Collected over 12 weeks post-final treatment, up to 6 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
truSculpt0/9 (0%)0/9 (0%)9/9 (100%)
Most frequent other events
Most frequent other events
EventtruSculpt
ErythemaSkin and subcutaneous tissue disorders9/9
PainSkin and subcutaneous tissue disorders2/9
TendernessSkin and subcutaneous tissue disorders1/9

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)truSculpt
<=18 years0
Between 18 and 65 years9
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)truSculpt
Female7
Male2
Race (NIH/OMB)
Race (NIH/OMB)(Participants)truSculpt
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander1
Black or African American0
White8
More than one race0
Unknown or Not Reported0
08

Study locations

3 sites
  • Cutera Research Center
    Brisbane, California 94005, United States
  • Skin Associates of South Florida
    Coral Gables, Florida 33146, United States
  • The Dermatology Institute of DuPage Medical Group
    Naperville, Illinois 60563, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2017 to primary completion in Mar 2018, 6 months.

Results were first posted in Sep 2023, 5 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2018
First posted
Feb 14, 2018
StartActual
Aug 17, 2017
Primary completionActual
Mar 7, 2018
CompletionActual
Mar 7, 2018
Results first posted
Sep 18, 2023
Last update
Sep 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03433430
Lead sponsor
Cutera Inc.
Responsible party
Sponsor
First posted
Feb 14, 2018
Start date
Aug 17, 2017
Primary completion
Mar 7, 2018
Completion
Mar 7, 2018
Results posted
Sep 18, 2023
Last update
Sep 18, 2023

Study contacts

Stephen Ronan, MD
principal investigator · Cutera Research Center
Ashish Bhatia, MD
principal investigator · The Dermatology Institute of DuPage Medical Group
Joely Kaufman, MD, FAAD
principal investigator · Skin Associates of South Florida

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion